Chronic stress is a significant risk factor that contributes to the progression of colorectal cancer (CRC) and has garnered considerable attention in recent research. It influences the distribution and function of immune cells within the intestinal mucosa through the "brain-gut" axis, altering cytokine and chemokine secretion and creating an immunosuppressive tumor microenvironment. The intestine, often called the "second brain," is particularly susceptible to the effects of chronic stress. Cytokines and chemokines in intestinal mucosal immunity(IMI) are closely linked to CRC cells' proliferation, metastasis, and drug resistance under chronic stress. Recently, antidepressants have emerged as potential therapeutic agents for CRC, possibly by modulating IMI to restore homeostasis and exert anti-tumor effects. This article reviews the role of chronic stress in promoting CRC progression via its impact on intestinal mucosal immunity, explores potential targets within the intestinal mucosa under chronic stress, and proposes new approaches for CRC treatment.
Sarcopenia, characterised by an ongoing loss of skeletal muscle mass and reduced strength and function, is frequently observed in patients with non-small cell lung cancer (NSCLC). However, the relationship between sarcopenia and the prognosis of NSCLC treated with immune checkpoint inhibitors (ICIs) remains unclear. This aimed to assess whether sarcopenia is an independent prognostic factor for survival in patients with advanced NSCLC receiving ICIs. For this retrospective cohort study, we analysed the medical records of patients attending our hospital aged 18–75 years who were newly diagnosed with stage IIIB to stage IV NSCLC, and who had received ICIs as first- or second-line therapy between May 2019 and April 2022. The skeletal muscle index (SMI) was calculated from computed tomography (CT) images and relevant clinical characteristics within 4 weeks of initiating treatment and used to diagnose sarcopenia status. The Kaplan-Meier method and log-rank test were used to calculate and compare patients' progression-free survival (PFS). Cox proportional hazard regression was used to examine the associations between sarcopenia and survival outcomes. The chi-square test was used to compare treatment response outcomes, such as the objective response rate (ORR), disease control rate (DCR), and immunotherapy-related adverse events (irAEs), between individuals with and without sarcopenia. Additionally, the Student's t-test was utilised to compare SMI values between patients by their objective response (OR) and disease control (DC). Finally, the Mann-Whitney U test was used to compare nutritional and inflammatory indicators between the sarcopenia groups. The study enrolled 70 patients, of whom 34 (48.6%) were diagnosed with sarcopenia. The median PFS of patients with and without sarcopenia was 7.5 vs. 13.4 months, respectively (p = 0.006). The proportional hazards regression analysis showed sarcopenia to be an independent prognostic factor for shorter PFS (hazard ratio (HR): 0.504, 95% CI: 0.265–0.962, p = 0.038). Using chi square tests, we found significant differences in the ORR (20.59% vs. 58.33%, p = 0.001) and occurrence of any irAEs (44.1% vs. 22.2%, p = 0.028) between the sarcopenia and the non-sarcopenia groups, respectively. The Student's t-test showed a significant difference in SMI between the ORR group and the non-ORR group (49.99 ± 7.00 vs. 42.98 ± 2.18 cm2/m2, p = 0.0015). While the sarcopenia group were with significantly a lower CD4+/CD8+ ratios and a higher C-reactive protein (CRP) level (p = 0.026, p = 0.011, respectively). Conclusions: This study found that sarcopenia is a significant predictor of a poor prognosis for patients with advanced NSCLC receiving ICIs. Multiple inflammatory and immune functions related to prognosis also differ by sarcopenia status.
Objective: Xiao‐Chai‐Hu‐Tang (XCHT) has been demonstrated to exert an antidepressant effect during long‐term clinical practices. However, the potential mechanisms of XCHT remain unknown. This study aims to investigate the effect of XCHT on chronic unpredictable mild stress‐induced mice with depressive‐like behaviors and to explore the underlying mechanisms. Methods: The active compositions and potential related targets of XCHT in the brain were obtained through UPLC‐Q‐TOF‐MS, network pharmacology, and bioinformatics analyses, verified by experimental validation. Then, the protein–protein interaction (PPI), Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses, and molecular docking were used to predict the core targets and mechanisms of XCHT on depression. After being treated with XCHT standard decoction, based on enzyme‐linked immunosorbent assay (ELISA), non‐targeted metabolism, targeted LC–MS analyses, RNA‐seq, quantitative RT‐PCR, immunofluorescence, and western blotting were determined to clarify the mechanism of XCHT in the treatment of anxiety and depression disorder. Results: In total, 166 active ingredients and 525 related targets of XCHT were detected and selected from the network databases. The inflammatory response and metabolism of neurotransmitters were the main related signaling pathways predicted by KEGG enrichment analyses. Behavioral testing shows that XCHT has antidepressant effects, and untargeted metabolomic studies showed it significantly reduced levels of the neurotoxic substance quinoline acid. Combining the results of molecular docking, RNA‐seq, and western blot revealed that XCHT regulated nerve regeneration via BDNF/TrkB/CREB and PI3K/AKT signaling pathways. Immunofluorescence analysis revealed that XCHT downregulated the chronic stress‐induced activation of microglia and astrocytes in the hippocampus. Conclusion: XCHT exerts antidepressant functions by modulating neuroinflammation and neuroregeneration.
Objective: This study aimed to integrate bioinformatics, network pharmacology, and single-cell sequencing to explore the potential neuro-immune mechanisms by which the traditional Chinese medicine formula Xiao-Yao-San (XYS) ameliorates chronic stress-induced colorectal cancer (CRC) progression. Methods: Transcriptomic and survival data of CRC patients were obtained from public databases (TCGA, GEO). Combined with literature review, 130 neurotransmitter-related receptor genes (NRGs) were screened, and their expression and prognostic value in CRC were analyzed. Based on 51 XYS components previously identified by UHPLC/Q-TOF-MS, network pharmacology was employed to predict their potential targets (1,228 in total). These targets were intersected with differentially expressed NRGs. Molecular docking was further performed to evaluate the binding affinity between XYS components and receptors. A mouse model of chronic unpredictable mild stress (CUMS) combined with orthotopic CRC transplantation was established. Neurotransmitter levels were measured by mass spectrometry, and 10x Genomics single-cell transcriptomic sequencing was applied to analyze changes in the tumor immune microenvironment. Results: Bioinformatics analysis revealed that 100 NRGs were significantly dysregulated in CRC tissues. After intersecting with XYS targets, 14 potential NRGs were identified, among which seven (ADRA2C, DRD1, GABRA2, HTR1B, HTR1D, HTR2A, HTR2B) showed significant correlation with patient prognosis. Molecular docking demonstrated favorable binding activity between XYS components (such as 8-Debenzoylpaeoniflorin and Sucrose) and the hub NRGs. In vivo experiments confirmed that XYS reversed CUMS-induced abnormalities in tumor and plasma levels of norepinephrine, dopamine, and serotonin. Single-cell sequencing further indicated that XYS reduced the CUMS-induced increase in myeloid-derived suppressor cell (MDSC) proportion and modulated the expression of key NRGs, including HTR2A in macrophages and HTR1B in T cells. KEGG enrichment analysis suggested that neuroactive ligand-receptor interaction and immune-related pathways were significantly regulated upon XYS intervention. Conclusion: XYS modulates neurotransmitter homeostasis and the tumor immune microenvironment in CRC under chronic stress through a multi-component and multi-target manner, which is closely associated with the regulation of key NRGs such as HTR1B and DRD1. This study provides neuro-immunological evidence for the clinical application of XYS in CRC patients with emotional disorders.